Immunohistochemical expression of RPRM is associated with low expression of proliferation marker Ki67 in patients with breast cancer
Immunohistochemical expression of RPRM is associated with low expression of proliferation marker Ki67 in patients with breast cancer
Authors
Buchegger, Kurt
Lopez, Jaime
Ili, Carmen
Riquelme, Ismael
Letelier, Pablo
Guzman, Pablo
Bellolio, Enrique
Corvalan, Alejandro H.
Brebi, Priscilla
Carlos Roa, Juan
Lopez, Jaime
Ili, Carmen
Riquelme, Ismael
Letelier, Pablo
Guzman, Pablo
Bellolio, Enrique
Corvalan, Alejandro H.
Brebi, Priscilla
Carlos Roa, Juan
Authors
Date
Datos de publicaciĆ³n:
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE,Vol.9,3025-3032,2016
Keywords
Collections
Abstract
Reprimo (RPRM) is a potential p53-dependent tumor suppressor gene, which plays an important role in cell cycle arrest at G(2)/M checkpoint. The aim of this study was to characterize RPRM protein expression in breast cancer tissues and its relation with clinic-pathologic features and proliferation marker protein Ki67. RPRM protein expression was examined by immunohistochemistry in tissue microarray containing 275-breast cancer and 16 normal breast tissues. These cases were classified as negative or positive expression for RPRM expression level with clinic-pathologic variables. The Kaplan-Meier curve was used to estimate survival over time. Positive expression of RPRM was observed in 68.4% (188/275) of tumors and 100% of breast normal tissues (16/16). RPRM expression has a significant relationship with age (P = 0.000). Moreover, positive RPRM expression was significant associated with low expression of proliferation marker protein Ki67; however, survival analysis did not show significant differences. These results suggest that RPRM is not a good prognosis marker but likely had an important role modulating negatively cell proliferation in breast cancer tissues.